MannKind Corp

🇺🇸United States
Ownership
-
Employees
414
Market Cap
$1.4B
Website

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

First Posted Date
2007-08-06
Last Posted Date
2012-06-26
Lead Sponsor
Mannkind Corporation
Target Recruit Count
12
Registration Number
NCT00511979

18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

First Posted Date
2007-08-06
Last Posted Date
2012-04-30
Lead Sponsor
Mannkind Corporation
Target Recruit Count
227
Registration Number
NCT00511732

Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

First Posted Date
2007-08-06
Last Posted Date
2012-04-30
Lead Sponsor
Mannkind Corporation
Target Recruit Count
123
Registration Number
NCT00511602

Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes

First Posted Date
2007-08-06
Last Posted Date
2011-06-29
Lead Sponsor
Mannkind Corporation
Target Recruit Count
13
Registration Number
NCT00511719

A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

First Posted Date
2007-05-21
Last Posted Date
2012-06-14
Lead Sponsor
Mannkind Corporation
Target Recruit Count
26
Registration Number
NCT00475371
Locations
🇳🇱

University Medical Centre Groningen, Zuidlaren, Netherlands

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

First Posted Date
2007-01-18
Last Posted Date
2010-08-03
Lead Sponsor
Mannkind Corporation
Target Recruit Count
12
Registration Number
NCT00423254
Locations
🇺🇸

Nevada Cancer Institute, Sparks, Nevada, United States

🇺🇸

Arizona Cancer Center, Tuscon, Arizona, United States

🇺🇸

Lombardi Comprehensive Cancer Center at Georgetown, Washington, District of Columbia, United States

and more 2 locations

To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.

Phase 2
Completed
Conditions
First Posted Date
2007-01-08
Last Posted Date
2009-10-14
Lead Sponsor
Mannkind Corporation
Target Recruit Count
16
Registration Number
NCT00419302
Locations
🇩🇪

Profil Institute for Metabolic Research, Hellersbergstr, Germany

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

First Posted Date
2006-06-02
Last Posted Date
2012-05-04
Lead Sponsor
Mannkind Corporation
Target Recruit Count
3
Registration Number
NCT00332826
Locations
🇨🇦

Finchlea Medical Group, Brampton, Ontario, Canada

🇺🇸

Executive Health and Research Associates Inc, Atlanta, Georgia, United States

🇺🇸

Pinaccle Trials Inc (SMO), Atlanta, Georgia, United States

and more 74 locations

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

First Posted Date
2006-06-01
Last Posted Date
2014-10-16
Lead Sponsor
Mannkind Corporation
Target Recruit Count
547
Registration Number
NCT00332488
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

🇺🇸

International Clinical Research Network, Chula Vista, California, United States

🇺🇸

James A Dicke MDPA, Towson, Maryland, United States

and more 115 locations

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

First Posted Date
2006-03-31
Last Posted Date
2014-10-16
Lead Sponsor
Mannkind Corporation
Target Recruit Count
677
Registration Number
NCT00309244
Locations
🇺🇸

Valley Research, Fresno, California, United States

🇺🇸

Physician's East PA, Greenville, North Carolina, United States

🇺🇸

Clintell Inc, Skokie, Illinois, United States

and more 146 locations
© Copyright 2024. All Rights Reserved by MedPath